$5.00
27.43% day before yesterday
Nasdaq, Jan 02, 10:16 pm CET
ISIN
US48669G1058
Symbol
KZIA

Kazia Therapeutics Ltd Sponsored ADR Stock price

$5.00
-5.06 50.30% 1M
-1.58 24.01% 6M
-1.89 27.43% YTD
-3.73 42.69% 1Y
-25.75 83.74% 3Y
-444.00 98.89% 5Y
-405.00 98.78% 10Y
-5,973.85 99.92% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-1.89 27.43%
ISIN
US48669G1058
Symbol
KZIA
Industry

Key metrics

Basic
Market capitalization
$11.5m
Enterprise Value
$11.0m
Net debt
positive
Cash
$2.9m
Shares outstanding
809.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
143.9 | 338.5
EV/Sales
137.3 | 322.9
EV/FCF
-
P/B
negative
Financial Health
Equity Ratio
-137.0%
Return on Equity
249.4%
ROCE
230.3%
ROIC
432.1%
Debt/Equity
-0.4
Financials (TTM | estimate)
Revenue
$80.0k | $34.0k
EBITDA
- | -
EBIT
$-12.3m | $-15.6m
Net Income
$-13.8m | $-646.8m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
-94.8% | -57.5%
EBITDA
- | -
EBIT
32.7% | -28.7%
Net Income
22.7% | -4,587.2%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-16,149.1%
Net
-18,159.7% | -1,902,137.0%
Free Cash Flow
-
More
EPS
$0.0
FCF per Share
-
Short interest
0.4%
Employees
13
Rev per Employee
$10.0k
Show more

Is Kazia Therapeutics Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:

Buy
88%
Hold
13%

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
0.08 0.08
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.81 5.81
36% 36%
7,263%
- Research and Development Expense 4.88 4.88
58% 58%
6,100%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -12 -12
33% 33%
-15,344%
Net Profit -14 -14
23% 23%
-17,250%

In millions USD.

Don't miss a Thing! We will send you all news about Kazia Therapeutics Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral
PRNewsWire
11 days ago
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY , Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therapies for cancer, today announced that it has regained full compliance with all applicable listing sta...
Neutral
PRNewsWire
23 days ago
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions in CTC and clusters SYDNEY , Dec. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or th...
Neutral
PRNewsWire
about one month ago
SYDNEY , Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities (PIPE). Pursuant to the securities purchase agreement, the Company agreed to offer and s...
More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office Australia
CEO John Friend
Employees 13
Founded 1994
Website www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today